NEW YORK, Sept. 5 - Bio-Quant has created a new division designed to offer screening technology for G protein-coupled receptors, the company said on Wednesday.

GPCRs function as the delivery mechanism for more than 50 percent of all drugs currently on the market. To facilitate the discovery of additional GPCRs that might serve as drug targets, Bio-Quant’s new business unit will provide platforms that screen for cell motility and GPCR activation.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.